Literature DB >> 31164318

Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.

Tomoo Ikari1, Jun Sakakibara-Konishi2, Gaku Yamamoto1, Hidenori Kitai1, Hidenori Mizugaki1, Hajime Asahina1, Eiki Kikuchi1, Naofumi Shinagawa1.   

Abstract

Entities:  

Keywords:  Compound mutation; EGFR mutation; EGFR-TKI; Lung adenocarcinoma; Uncommon mutation

Mesh：

Substances：

Year:  2019        PMID： 31164318     DOI： 10.1016/j.cllc.2019.05.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  1 in total

1.  First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.

Authors:  Noriaki Ito; Takeshi Masuda; Ikuko Ooka; Takatsune Hosoya; Kakuhiro Yamaguchi; Shinjiro Sakamoto; Yasushi Horimasu; Taku Nakashima; Shintaro Miyamoto; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Thorac Cancer       Date:  2022-01-25       Impact factor: 3.500
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.